Alector Shares Fall 35.6% After Co's Alzheimer’s Disease Drug Fails to Meet Main Goal of Mid-Stage Trial
alector股份暴跌35.6%,因公司阿爾茨海默病藥物未能達到中期試驗的主要目標
Alector Shares Fall 35.6% After Co's Alzheimer’s Disease Drug Fails to Meet Main Goal of Mid-Stage Trial
alector股份暴跌35.6%,因公司阿爾茨海默病藥物未能達到中期試驗的主要目標
譯文內容由第三人軟體翻譯。